Literature DB >> 17047115

A pilot study in patients with established advanced liver fibrosis using pirfenidone.

J Armendáriz-Borunda, M C Islas-Carbajal, E Meza-García, A R Rincón, S Lucano, A S Sandoval, A Salazar, J Berumen, A Alvarez, A Covarrubias, G Aréchiga, L García.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17047115      PMCID： PMC1860119          DOI： 10.1136/gut.2006.107136

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  5 in total

1.  Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference.

Authors:  S L Friedman; J J Maher; D M Bissell
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

Review 2.  Fibrosis in chronic liver diseases: diagnosis and management.

Authors:  Massimo Pinzani; Krista Rombouts; Stefano Colagrande
Journal:  J Hepatol       Date:  2004-12-24       Impact factor: 25.083

3.  Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

Authors:  H L Bonkovsky; J M Woolley
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2.

Authors:  A Di Sario; E Bendia; G Macarri; C Candelaresi; S Taffetani; M Marzioni; A Omenetti; S De Minicis; L Trozzi; A Benedetti
Journal:  Dig Liver Dis       Date:  2004-11       Impact factor: 4.088

5.  Pirfenidone effectively reverses experimental liver fibrosis.

Authors:  Leonel García; Ivan Hernández; Ana Sandoval; Adriana Salazar; Jesus Garcia; Jose Vera; G Grijalva; Pablo Muriel; Solomon Margolin; Juan Armendariz-Borunda
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083
  5 in total
  22 in total

Review 1.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

2.  Mitogen-activated Protein Kinase-activated Protein Kinase 2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis.

Authors:  Jiurong Liang; Ningshan Liu; Xue Liu; Jessica Monterrosa Mena; Ting Xie; Yan Geng; Caijuan Huan; Yanli Zhang; Forough Taghavifar; Guanling Huang; Adrianne Kurkciyan; Vivian Barron; Dianhua Jiang; Paul W Noble
Journal:  Am J Respir Cell Mol Biol       Date:  2019-01       Impact factor: 6.914

Review 3.  Experience of a single center with congenital hepatic fibrosis: a review of the literature.

Authors:  Ali Shorbagi; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

Review 4.  Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

5.  The multifaceted role of pirfenidone and its novel targets.

Authors:  José Macías-Barragán; Ana Sandoval-Rodríguez; Jose Navarro-Partida; Juan Armendáriz-Borunda
Journal:  Fibrogenesis Tissue Repair       Date:  2010-09-01

Review 6.  Therapeutic targets for treating fibrotic kidney diseases.

Authors:  So-Young Lee; Sung I Kim; Mary E Choi
Journal:  Transl Res       Date:  2014-08-13       Impact factor: 7.012

Review 7.  Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.

Authors:  Pei-Suen Tsou; Andrew J Haak; Dinesh Khanna; Richard R Neubig
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-16       Impact factor: 4.249

8.  Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study.

Authors:  Yani Liu; Jianhong Wu; Zhongfang Li; Ying Luo; Fandian Zeng; Shaojun Shi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

Review 9.  Emerging Agents for the Management of Nephrotic Syndrome: Progress to Date.

Authors:  Keisha L Gibson; Panupong Hansrivijit; Maria E Ferris
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022

Review 10.  Antifibrosis: to reverse the irreversible.

Authors:  Ziv Paz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.